AQST
Aquestive Therapeutics, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$4.61
−1.07%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$4.64
From 52W high−38.45%
Volume3.42M
Market cap$578.61M
P/E (TTM)—
P/S (TTM)10.7x
Div yield—
Key dataSep 18, 2026
Open
$4.64
From 52W high
−38.45%
Volume
3.42M
Market cap
$578.61M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−8.8x
P/E (TTM)
—
RSI (14)
42.6
MomentumView details →
1D Return
−1.07%
YTD Return
−29.49%
SummaryUpdated Jun 1, 2026
Aquestive Therapeutics, Inc. (NASDAQ:AQST) is a specialty pharmaceutical company founded in 2004 and headquartered in Warren, New Jersey. The company went public in July 2018 and focuses on developing and commercializing innovative drug delivery technologies, particularly through its proprietary oral soluble film platform. Aquestive has evolved from a contract manufacturing organization into a fully integrated pharmaceutical company with both commercial products and a robust pipeline of proprietary drug candidates targeting various therapeutic areas including epilepsy, anaphylaxis, ADHD, and rare diseases.
Similar companies
Latest newsMore news →
Aquestive Therapeutics resubmitted its New Drug Application to the U.S. Food and Drug Administration for Anaphylm (dibutepinephrine) sublingual film for the treatment of Type I allergic reactions, including anaphylaxis.3d agoAquestive Therapeutics reported its financial results for the second quarter ended June 30, 2026.40d ago